Terns Pharmaceuticals Inc

NASDAQ:TERN   4:00:00 PM EDT
5.86
-0.23 (-3.78%)
4:01:31 PM EDT: $5.86 0.00 (0.00%)
Products, Regulatory

Terns Pharmaceuticals Highlights Results From Phase 1 Clinical Trial Of TERN-501 At AASLD The Liver Meeting 2022

Published: 11/04/2022 12:21 GMT
Terns Pharmaceuticals Inc (TERN) - Terns Pharmaceuticals Highlights Results From Phase 1 Clinical Trial of Tern-501 at Aasld the Liver Meeting® 2022.
Terns Pharmaceuticals Inc - Data Demonstrated Treatment With Tern-501 Resulted in Time- and Dose-dependent Increases in Sex Hormone Binding Globulin.
Terns Pharmaceuticals Inc - Phase 2a Duet Trial Evaluating Tern-501 Alone and in Combination With Tern-101.